Rapport Therapeutics (RAPP) Competitors $22.56 -1.44 (-6.00%) (As of 11:45 AM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends RAPP vs. AGIO, MRUS, ARWR, XENE, ZLAB, VERA, VRNA, EWTX, KYMR, and SWTXShould you be buying Rapport Therapeutics stock or one of its competitors? The main competitors of Rapport Therapeutics include Agios Pharmaceuticals (AGIO), Merus (MRUS), Arrowhead Pharmaceuticals (ARWR), Xenon Pharmaceuticals (XENE), Zai Lab (ZLAB), Vera Therapeutics (VERA), Verona Pharma (VRNA), Edgewise Therapeutics (EWTX), Kymera Therapeutics (KYMR), and SpringWorks Therapeutics (SWTX). These companies are all part of the "pharmaceutical products" industry. Rapport Therapeutics vs. Agios Pharmaceuticals Merus Arrowhead Pharmaceuticals Xenon Pharmaceuticals Zai Lab Vera Therapeutics Verona Pharma Edgewise Therapeutics Kymera Therapeutics SpringWorks Therapeutics Agios Pharmaceuticals (NASDAQ:AGIO) and Rapport Therapeutics (NASDAQ:RAPP) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, profitability, valuation, risk, community ranking, dividends and earnings. Does the media favor AGIO or RAPP? In the previous week, Agios Pharmaceuticals had 7 more articles in the media than Rapport Therapeutics. MarketBeat recorded 12 mentions for Agios Pharmaceuticals and 5 mentions for Rapport Therapeutics. Agios Pharmaceuticals' average media sentiment score of 1.66 beat Rapport Therapeutics' score of 0.71 indicating that Agios Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Agios Pharmaceuticals 10 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Rapport Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts recommend AGIO or RAPP? Agios Pharmaceuticals presently has a consensus price target of $52.33, suggesting a potential downside of 11.10%. Rapport Therapeutics has a consensus price target of $35.00, suggesting a potential upside of 45.83%. Given Rapport Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Rapport Therapeutics is more favorable than Agios Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Agios Pharmaceuticals 0 Sell rating(s) 4 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.50Rapport Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has preferable valuation and earnings, AGIO or RAPP? Rapport Therapeutics has lower revenue, but higher earnings than Agios Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAgios Pharmaceuticals$26.82M125.18-$352.09M$11.365.18Rapport TherapeuticsN/AN/A-$34.79MN/AN/A Is AGIO or RAPP more profitable? Agios Pharmaceuticals has a net margin of 2,051.38% compared to Rapport Therapeutics' net margin of 0.00%. Rapport Therapeutics' return on equity of 0.00% beat Agios Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Agios Pharmaceuticals2,051.38% -2.93% -2.58% Rapport Therapeutics N/A N/A N/A Does the MarketBeat Community prefer AGIO or RAPP? Agios Pharmaceuticals received 485 more outperform votes than Rapport Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Rapport Therapeutics an outperform vote while only 66.90% of users gave Agios Pharmaceuticals an outperform vote. CompanyUnderperformOutperformAgios PharmaceuticalsOutperform Votes48766.90% Underperform Votes24133.10% Rapport TherapeuticsOutperform Votes2100.00% Underperform VotesNo Votes SummaryAgios Pharmaceuticals and Rapport Therapeutics tied by winning 6 of the 12 factors compared between the two stocks. Ad Porter & CompanyThis company will win the AI race Rome wasn’t built in a day… But there is another lesser-known type of keystone, one that plays an equally critical role in supporting the most revolutionary technology the world’s ever seen… artificial intelligence. And without it, the entire AI industry would collapse. You must read this new presentation from Porter Stansberry. Get Rapport Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RAPP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RAPP vs. The Competition Export to ExcelMetricRapport TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$854.88M$6.73B$5.20B$8.97BDividend YieldN/A7.94%5.23%4.04%P/E RatioN/A4.7285.7113.39Price / SalesN/A352.931,469.4286.49Price / CashN/A22.8835.2935.09Price / BookN/A5.604.914.96Net Income-$34.79M$151.32M$117.36M$224.10M7 Day Performance4.61%3.14%2.75%2.01%1 Month Performance-5.08%-1.67%1.71%9.79%1 Year PerformanceN/A31.88%36.01%29.97% Rapport Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RAPPRapport Therapeutics2.4216 of 5 stars$22.56-6.0%$35.00+55.1%N/A$825.25MN/A0.00N/AShort Interest ↓Lockup ExpirationGap UpAGIOAgios Pharmaceuticals3.8143 of 5 stars$59.06-0.6%$52.33-11.4%+157.1%$3.37B$26.82M5.23390Positive NewsMRUSMerus2.5478 of 5 stars$49.17+9.7%$85.45+73.8%+93.1%$3.37B$43.95M-12.0337Analyst ForecastNews CoverageARWRArrowhead Pharmaceuticals4.2731 of 5 stars$26.03-0.5%$40.70+56.4%+13.7%$3.24B$3.55M-5.19400XENEXenon Pharmaceuticals2.8921 of 5 stars$42.20-1.0%$57.45+36.1%+14.5%$3.22B$9.43M0.00251Positive NewsZLABZai Lab2.6856 of 5 stars$28.99+0.5%$52.50+81.1%+6.2%$3.15B$266.72M0.002,175Gap UpVERAVera Therapeutics2.5436 of 5 stars$49.71-0.1%$59.22+19.1%+258.0%$3.15BN/A-19.2440VRNAVerona Pharma1.4564 of 5 stars$39.11-1.3%$43.83+12.1%+189.3%$3.13B$460,000.000.0030Insider TradeShort Interest ↓Positive NewsEWTXEdgewise Therapeutics3.5946 of 5 stars$33.00+2.5%$42.33+28.3%+409.5%$3.12BN/A-22.0060Short Interest ↓News CoverageKYMRKymera Therapeutics2.3116 of 5 stars$47.99+2.4%$53.40+11.3%+129.9%$3.11B$87.56M-20.02170Analyst UpgradeNews CoveragePositive NewsSWTXSpringWorks Therapeutics1.9398 of 5 stars$41.54+0.1%$69.50+67.3%+31.3%$3.09B$135.49M-10.69305Positive News Related Companies and Tools Related Companies AGIO Competitors MRUS Competitors ARWR Competitors XENE Competitors ZLAB Competitors VERA Competitors VRNA Competitors EWTX Competitors KYMR Competitors SWTX Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:RAPP) was last updated on 12/3/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredIs NVDA a sell? Buy this stock instead before Dec 3After months of speculation that Nvidia was "cooling off..." and "running out of steam..." The company is m...Chaikin Analytics | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rapport Therapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Share Rapport Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
